Cargando…
Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec
BACKGROUND: The 21-gene Breast Recurrence Score (RS) assay, “the assay”, has led to a paradigm shift for patients with hormone receptor-positive, node-negative early breast cancer and is emerging as an important tool to assist physician-patient decisions in foregoing chemotherapy in node-positive pa...
Autores principales: | Hassan, Saima, Younan, Rami, Patocskai, Erica, Provencher, Louise, Poirier, Brigitte, Sideris, Luca, Dubé, Pierre, Mihalcioiu, Catalin, Chabot-Blanchet, Malorie, Guertin, Marie-Claude, Boileau, Jean-François, Robidoux, André |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526502/ https://www.ncbi.nlm.nih.gov/pubmed/35830543 http://dx.doi.org/10.1093/oncolo/oyac123 |
Ejemplares similares
-
Survival After Sentinel Lymph Node Biopsy Compared with Axillary Lymph Node Dissection for Female Patients with T3-4c Breast Cancer
por: Li, Peiyong, et al.
Publicado: (2023) -
Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy
por: Ling, Diane C., et al.
Publicado: (2019) -
Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools
por: Marino, Maria Adele, et al.
Publicado: (2019) -
Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes
por: Xu, Amy J., et al.
Publicado: (2019) -
Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial?
por: Gebhardt, Brian J., et al.
Publicado: (2018)